Recent advances in anti-infectious chemotherapy: ertapenem, voriconazole, malarone
JBMS-Journal of the Bahrain Medical Society. 2003; 15 (4): 240-246
in English
| IMEMR
| ID: emr-62435
ABSTRACT
To assess the current knowledge of the clinical uses of ertapenem voriconazole and malarone, we explored articles published in the scientific literature. A benefit from ertapenem is documented in postsurgical abdominal infections including gynecological surgery. Ertapenem covers a wide spectrum of pathogens including anaerobes better than ceftriaxone and requires a lower number of injections compared to piperacillin-tazobactam. It should not be used in hospital acquired infections. Its use in community-acquired pneumonia is limited. Voriconazole shows favorable in vitro activity against yeasts including Cryptococcus spp, dimorphic fungi and several molds. Zygomycetes require considerably high MICs, It has less toxic effects such as infusion- related reactions and kidney damage, although more episodes of hallucinations have been observed. Malarone [atovaquone plus proguanil] is an Option for treatment and prophylaxis of malaria but routine use is not recommended. No clear superiority exists among the available regimens
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Triazoles
/
Carbapenems
/
Lactams
Limits:
Humans
Language:
English
Journal:
J. Bahrain Med. Soc.
Year:
2003
Similar
MEDLINE
...
LILACS
LIS